<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704219</url>
  </required_header>
  <id_info>
    <org_study_id>3475-B61</org_study_id>
    <secondary_id>MK-3475-B61</secondary_id>
    <secondary_id>2020-004087-26</secondary_id>
    <nct_id>NCT04704219</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)</brief_title>
  <acronym>KEYNOTE-B61</acronym>
  <official_title>A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed as a single-arm open-label study in order to rapidly provide&#xD;
      information on the potential benefits of the combination of pembrolizumab and lenvatinib in&#xD;
      participants with previously untreated advanced/metastatic non-clear cell renal cell&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">October 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Objective Response Rate (ORR) is defined as the percentage of participants with a complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors 1.1 (RECIST 1.1) by blinded independent central review (BICR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
    <description>Duration of Response (DOR) is defined for participants who demonstrate confirmed CR or PR as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
    <description>Progression-free Survival (PFS) is defined as the time from the date of first dose to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
    <description>Overall Survival (OS) is defined as the time from date of first dose until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Ratio (CBR)</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
    <description>Clinical Benefit Ratio (CBR) is defined as the percentage of participants who achieved CR, PR, or stable disease (SD) for at least 6 months per RECIST 1.1 by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
    <description>Disease Control Rate (DCR) is defined as the percentage of participants who achieved CR, PR, or SD per RECIST 1.1 by BICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced One or More Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Medication Due to an AE</measure>
    <time_frame>Up to approximately 4.5 years</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation.</description>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.</description>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <other_name>LENVIMA®</other_name>
    <other_name>Kisplyx</other_name>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have a histologically-confirmed diagnosis of non-clear cell RCC.&#xD;
&#xD;
          2. Has locally advanced/metastatic disease (ie, Stage IV per the American Joint Committee&#xD;
             on Cancer).&#xD;
&#xD;
          3. Has received no prior systemic therapy for advanced nccRCC. Note: Prior&#xD;
             neoadjuvant/adjuvant therapy for nccRCC is acceptable if completed &gt;12 months prior to&#xD;
             allocation.&#xD;
&#xD;
          4. Male participants agree to use approved contraception during the treatment period for&#xD;
             at least 7 days after the last dose of study medication, or refrain from heterosexual&#xD;
             intercourse during this period.&#xD;
&#xD;
          5. Female participants are not pregnant or breastfeeding, and are not a woman of&#xD;
             childbearing potential (WOCBP), OR are a WOCBP that agrees to use contraception during&#xD;
             the treatment period and for at least 120 days post pembrolizumab, or 30 days post&#xD;
             lenvatinib, whichever occurs last.&#xD;
&#xD;
          6. Has measurable disease per RECIST 1.1 as assessed by BICR. Lesions situated in a&#xD;
             previously irradiated area are considered measurable if progression has been&#xD;
             demonstrated in such lesions.&#xD;
&#xD;
          7. Has submitted an archival tumor tissue sample or newly obtained core or incisional&#xD;
             biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded&#xD;
             (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to&#xD;
             archived tissue.&#xD;
&#xD;
          8. Has Karnofsky Performance Status (KPS) ≥70% as assessed within 10 days prior to the&#xD;
             start of study intervention.&#xD;
&#xD;
          9. Has adequately controlled blood pressure with or without antihypertensive medications&#xD;
&#xD;
         10. Have adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has collecting duct histology.&#xD;
&#xD;
          2. A WOCBP who has a positive urine pregnancy test within 24 hours before the first dose&#xD;
             of study intervention.&#xD;
&#xD;
          3. Has a left ventricular ejection fraction below the institutional (or local laboratory)&#xD;
             normal range.&#xD;
&#xD;
          4. Has radiographic encasement or invasion of a major blood vessel, or of intratumoral&#xD;
             cavitation.&#xD;
&#xD;
          5. Has clinically significant cardiovascular disease within 12 months from first dose of&#xD;
             study intervention.&#xD;
&#xD;
          6. Has gastrointestinal malabsorption, gastrointestinal anastomosis, or any other&#xD;
             condition that might affect the absorption of lenvatinib.&#xD;
&#xD;
          7. Has active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior&#xD;
             to the first dose of study drug.&#xD;
&#xD;
          8. Has had major surgery within 3 weeks prior to first dose of study intervention.&#xD;
&#xD;
          9. Has received prior therapy with an anti-programmed cell-death 1 (PD-1),&#xD;
             anti-programmed cell-death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2&#xD;
             (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell&#xD;
             receptor (e.g., CTLA-4, OX-40, CD137).&#xD;
&#xD;
         10. Has received prior systemic anticancer therapy including investigational agents within&#xD;
             4 weeks prior to allocation.&#xD;
&#xD;
         11. Has received prior radiotherapy within 2 weeks of start of study intervention.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted&#xD;
             for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system&#xD;
             (CNS) disease.&#xD;
&#xD;
         12. Has received a live or attenuated vaccine within 30 days before the first dose of&#xD;
             study intervention.&#xD;
&#xD;
         13. Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks prior to the first dose of&#xD;
             study intervention.&#xD;
&#xD;
         14. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior the first dose of study intervention.&#xD;
&#xD;
         15. Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years.&#xD;
&#xD;
             Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of&#xD;
             the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that&#xD;
             have undergone potentially curative therapy are not excluded.&#xD;
&#xD;
         16. Has known active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
         17. Has severe hypersensitivity (≥Grade 3) to pembrolizumab, lenvatinib and/or any of&#xD;
             their excipients.&#xD;
&#xD;
         18. Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
&#xD;
         19. Has a history of (noninfectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease.&#xD;
&#xD;
         20. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         21. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is&#xD;
             required unless mandated by local health authority.&#xD;
&#xD;
         22. Has a known history of Hepatitis B (defined as HBsAg reactive) or known active&#xD;
             Hepatitis C virus.&#xD;
&#xD;
         23. Has a known history of active tuberculosis (TB; Bacillus tuberculosis).&#xD;
&#xD;
         24. Has had an allogenic tissue/solid organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Medical Center ( Site 0001)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-687-1116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center ( Site 0004)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>406-238-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada ( Site 0010)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>702-952-3400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center ( Site 0015)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-639-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center ( Site 0011)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>215-728-3889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center ( Site 0008)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-936-8422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance ( Site 0014)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-598-3300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MEDICAL COLLEGE OF WISCONSIN ( Site 0006)</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>414-805-8943</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University-MQ Health Clinical Trials Unit ( Site 0405)</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61298123635</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle ( Site 0403)</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61240143282</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61736467712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre Research ( Site 0404)</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61782922240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health ( Site 0400)</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61385722020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital ( Site 0402)</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61861526712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Cancer Vancouver-Clinical Trials Unit ( Site 1500)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604-877-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre ( Site 1501)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>416-480-5000x7433</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 1504)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>416-946-4501 ext. 2662</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 1502)</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R 3S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>418-525-4444 ext. 16848</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie Strasbourg Europe (ICANS) ( Site 1007)</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33368766767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse ( Site 1000)</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33231063106</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Cancérologie du Grand Montpellier ( Site 1005)</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc-Roussillon</state>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0033467926155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>centre hospitalier lyon sud ( Site 1003)</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Rhone</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33478864324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy ( Site 1002)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142115410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás C</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>36302780644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 0303)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5004</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet-Urogenital Tumors Department and Clinical Pharmacology ( Site 0304)</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612248600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0300)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tallaght University Hospital ( Site 1600)</name>
      <address>
        <city>Dublin</city>
        <zip>D24 NR0A</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35314144299</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 0901)</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390630154953</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0903)</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390223904450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0902)</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390458123876</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria Terni-SC Oncologia ( Site 0900)</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390744205631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1302)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82222288138</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center-Department of Oncology ( Site 1300)</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82230105977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 1301)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82234101767</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luxmed Onkologia sp. z o. o. ( Site 0802)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>48691666578</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225462331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-chemotherapy department ( Site 0800)</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48601569568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Scientific Center of Radiology-Russian Scientific Center of Radiology ( Site 0602)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117485</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79166590224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 0605)</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Volga District Medical Center-Urology Department ( Site 0604)</name>
      <address>
        <city>Nizhny Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79519068094</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SHBI Leningrad Regional Clinical Oncology Dispensary-Clinical Trials Department ( Site 0607)</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79817217460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 0200)</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34913368263</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0202)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961104605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0201)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34934894350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Cerrahpasa ( Site 1104)</name>
      <address>
        <city>Istanbul- Fatih</city>
        <state>Istanbul</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905334318506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Medicine of Faculty ( Site 1102)</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905334318506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara University Hospital Cebeci ( Site 1105)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905334318506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi-oncology hospital ( Site 1101)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905334318506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1103)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905334318506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cherkasy Regional Oncology Dispensary ( Site 0504)</name>
      <address>
        <city>Cherkassy</city>
        <state>Cherkaska Oblast</state>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380472319418</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chernihiv Medical Center of Modern Oncology ( Site 0509)</name>
      <address>
        <city>Chernihiv</city>
        <state>Chernihivska Oblast</state>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380507058899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnepropetrovsk Regional Clinical Hospital Mechnikov-Department of urology ( Site 0508)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380505896241</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CNPE &quot;Regional Center of Oncology&quot;-oncourology department ( Site 0502)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380508266088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital ( Site 1200)</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>01223 216083</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie ( Site 1205)</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44 (0) 161 918 7887</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Lenvatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

